IMS Health and Quintiles Announce Key Officers for Merged Company DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)

Health and Quintiles Announce Key Officers for Merged Company

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--August

29, 2016--IMS Health Holdings, Inc. (NYSE:IMS) and Quintiles

Transnational Holdings Inc. (NYSE:Q) today announced key senior

management roles in the future Quintiles IMS corporate leadership team,

subject to the completion of the merger.

Senior functional leaders reporting to Chairman and Chief Executive

Officer Ari Bousbib will include Michael McDonnell, EVP and Chief

Financial Officer; James Erlinger, EVP and General Counsel; and Trudy

Stein, EVP and Chief Human Resources Officer.

Global business leaders reporting to Mr. Bousbib will include, for the

clinical research business, Tom Pike, Vice Chairman and President,

Research & Development Solutions; and for the commercial business, Kevin

Knightly, President, Information and Technology Solutions; Jos Luis

Fern ndez, President, Global Services; Jon Resnick, President,

Real-World Insights; and Scott Evangelista, President, Contract Sales

"I am proud to be part of a leadership team with deep industry

knowledge, a proven track record of success and a commitment to

transforming healthcare for the better," said Ari Bousbib. "That

commitment extends across the 50,000 talented professionals who will

soon become part of one global team. Together, we are making excellent

progress on our integration planning and are confident that we will be

ready for a strong start on day one of the merger."

IMS Health (NYSE:IMS) is a leading global information and technology

services company providing clients in the healthcare industry with

end-to-end solutions to measure and improve their performance. Our 7,000

services experts connect configurable SaaS applications to 15+ petabytes

of complex healthcare data in the IMS One cloud platform, delivering

unique insights into diseases, treatments, costs and outcomes. The

company's 15,000 employees blend global consistency and local market

knowledge across 100 countries to help clients run their operations more

efficiently. Customers include pharmaceutical, consumer health and

medical device manufacturers and distributors, providers, payers,

government agencies, policymakers, researchers and the financial

As a global leader in protecting individual patient privacy, IMS Health

uses anonymous healthcare data to deliver critical, real-world disease

and treatment insights. These insights help biotech and pharmaceutical

companies, medical researchers, government agencies, payers and other

healthcare stakeholders to identify unmet treatment needs and understand

the effectiveness and value of pharmaceutical products in improving

overall health outcomes. Additional information is available at www.imshealth.com.

Quintiles (NYSE:Q) helps biopharma and other healthcare companies

improve their probability of success by connecting insights from our

deep scientific, therapeutic and analytics expertise with superior

delivery for better outcomes. From advisory through operations,

Quintiles is the world's largest provider of product development and

integrated healthcare services, including commercial and observational

solutions. Conducting operations in approximately 100 countries,

Quintiles is a member of the Fortune 500 and has been named to Fortune's

list of the "World's Most Admired Companies." To learn more, visit www.quintiles.com.

Important Information about the Transaction and Where to Find It

In connection with the proposed transaction, IMS Health and Quintiles

have filed documents with the SEC, including the filing by Quintiles of

a registration statement on Form S-4 that includes a joint proxy

statement that also constitutes a prospectus of Quintiles. The

registration statement, as amended, was declared effective on August 15,

2016 by the SEC. Quintiles filed the definitive joint proxy

statement/prospectus with the SEC on August 16, 2016. On August 19,

2016, each of IMS Health and Quintiles mailed that document to their

respective shareholders and may also file other documents with the SEC

regarding the proposed transaction. This document is not a substitute

for the joint proxy statement/prospectus or registration statement or

any other document which IMS Health or Quintiles may file with the SEC. Investors

and security holders of IMS Health and Quintiles are urged to read the

registration statement, the joint proxy statement/prospectus and any

other relevant documents, as well as any amendments or supplements to

these documents, carefully and in their entirety when they become

available because they will contain important information. Investors

and security holders may obtain free copies of the registration

statement and the joint proxy statement/prospectus and other documents

filed with the SEC by IMS Health and Quintiles through the web site

maintained by the SEC at www.sec.gov or by contacting the

investor relations department of IMS Health or Quintiles at the

No Offer or Solicitation

This communication is not intended to and shall not constitute an offer

to sell or the solicitation of an offer to sell or the solicitation of

an offer to buy any securities or a solicitation of any vote of

approval, nor shall there be any sale of securities in any jurisdiction

in which such offer, solicitation or sale would be unlawful prior to

registration or qualification under the securities laws of any such

jurisdiction. No offer of securities shall be made except by means of a

prospectus meeting the requirements of Section 10 of the Securities Act

of 1933, as amended.

Click here to subscribe to Mobile Alerts for Quintiles.

IMS Health Media Relations

Health Investor Relations

Tom Kinsley, +1-203-448-4691

Phil Bridges, +1-919-998-1653

Todd Kasper, +1-919-998-2590